Ascendis Pharma AS

$175.94
(as of Jun 6, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Ascendis Pharma AS

Stock Price
$175.94
Ticker Symbol
ASND
Exchange
NASDAQ

Industry Information for Ascendis Pharma AS

Sector
Healthcare
Industry
Biotechnology

Company Description for Ascendis Pharma AS

Website
https://ascendispharma.com
Country
USA
Full Time Employees
1,017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Fundamentals for Ascendis Pharma AS

Market Capitalization
$10,507,237,376
EBITDA
$-328,827,008
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-6.57
Earnings per Share Estimate Next Year
Profit Margin
-92.67%
Shares Outstanding
60,494,200
Percent Owned by Insiders
0.78%
Percent Owned by Institutions
113.36%
52-Week High
52-Week Low

Technical Indicators for Ascendis Pharma AS

50-Day Moving Average
200-Day Moving Average
RSI
65.84
ATR
7.71

Analyst Ratings for Ascendis Pharma AS

Strong Buy
12
Buy
4
Hold
0
Sell
0
Strong Sell
0

News About Ascendis Pharma AS

Jun 2, 2025, 4:21 PM EST
[DNA mutations or genetic disorder concept background] See more.
Jun 2, 2025, 8:25 AM EST
(RTTNews) - Ascendis Pharma (ASND) announced the FDA has accepted for priority review its New Drug Application for TransCon CNP for the treatment of children with achondroplasia and has set a PDUFA goal date of November 30, 2025 to complete its review. See more.
Jun 2, 2025, 8:00 AM EST
Ascendis Pharma See more.
May 19, 2025, 1:45 PM EST
As the U.S. market grapples with mixed stock performances and rising Treasury yields following a recent credit rating downgrade, investor sentiment remains cautious yet hopeful amid ongoing economic uncertainties. See more.